Introduction
Thromopag 25 is a brand name for eltrombopag, an oral thrombopoietin receptor agonist (TPO-RA). It stimulates platelet production by binding to the thrombopoietin (TPO) receptor on bone marrow megakaryocytes. It is primarily used to treat chronic immune thrombocytopenia (ITP) and other conditions associated with low platelet counts.
Storage
-
Store at room temperature (20–25°C) in a dry place.
-
Keep the tablets in their original blister pack to protect from moisture.
-
Do not refrigerate or freeze.
Use (Indications)
-
Chronic Immune Thrombocytopenia (ITP) – For adults and children (≥1 year) who have not responded adequately to corticosteroids or immunoglobulins.
-
Chronic Hepatitis C-Associated Thrombocytopenia – Helps increase platelet counts before antiviral therapy.
-
Severe Aplastic Anemia (SAA) – Used in combination with immunosuppressive therapy in patients who are ineligible for hematopoietic stem cell transplant.
Clinical Significance
-
Increases platelet counts, reducing the risk of bleeding.
-
Reduces dependency on platelet transfusions and corticosteroids.
-
Improves quality of life in chronic ITP patients.
-
Oral administration (more convenient than injectable alternatives like romiplostim).
Drawbacks
-
High cost (expensive long-term treatment).
-
Requires strict monitoring (risk of excessive platelet increase leading to thrombosis).
-
Not a cure – Platelet counts may drop after discontinuation.
-
Food and drug interactions (must be taken on an empty stomach, avoid calcium-rich foods, and certain medications like antacids).
Side Effects
Common Side Effects | Serious Side Effects |
---|---|
– Headache | – Thrombosis (blood clots) |
– Nausea | – Liver toxicity (requires regular LFT monitoring) |
– Fatigue | – Bone marrow fibrosis (rare, long-term use) |
– Diarrhea | – Increased risk of cataracts (monitor eye exams) |
– Rash | – Hematologic malignancies (theoretical risk) |
Conclusion
Thromopag 25 (eltrombopag) is an effective oral treatment for chronic ITP, hepatitis C-related thrombocytopenia, and severe aplastic anemia. While it significantly improves platelet counts and reduces bleeding risk, it requires careful monitoring for liver toxicity, thrombosis, and other potential complications. It is a valuable option for patients who do not respond to first-line therapies but must be used under strict medical supervision.
Reviews
There are no reviews yet.